跳至主要内容
临床试验/RPCEC00000330
RPCEC00000330尚未招募2 期

Evaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19)

Center for Genetic Engineering and Biotechnology (CIGB), in Havana0 个研究点目标入组 60 人开始时间: 2020年8月11日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
18 years 至 one(—)
性别
All

入选标准

  • 1) Patients aged = 18 years.
  • 2) Virological diagnosis by RT-PCR of infection to SARS-CoV-2.
  • 3) Patients in serious or critical condition.
  • 4) Acute respiratory failure according to clinical and Berlin criteria (imaging and oxygenation).
  • 5) Voluntariness of the patient through informed consent.

排除标准

  • 1) Previous treatment with JAK inhibitor, tocilizumab or other anti-IL6R or IL-6, IL-1 inhibitor (Anakinra).
  • 2) Patients with kidney disease on hemodialysis.
  • 3) Patients who previously indicate NO intubation, NO resuscitation.
  • 4) Known hypersensitivity to any of the components of the formulations under study.
  • 5) Pregnancy or breastfeeding.

研究者

发起方
Center for Genetic Engineering and Biotechnology (CIGB), in Havana

相似试验